Printer Friendly

CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO COMMENTS ON DEPRENYL RESEARCH LTD. PRESS RELEASE

 CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO COMMENTS
 ON DEPRENYL RESEARCH LTD. PRESS RELEASE
 VANCOUVER, British Columbia, Nov. 25 /PRNewswire/ -- Canguard Health Technologies Inc. responded today to the press release of November 22, 1991 in which Deprenyl Research Ltd.(Toronto: DEP, NASDAQ: DEPLF) alleged incorrectly that Canguard is preparing to sell a generic copy of ELDEPRYL.
 In fact Canguard and its corporate partner, Pharmascience Inc., an established pharmaceutical company in Montreal, are developing a competing brand name product, PARKINYL, which Pharmascience will manufacture for world markets and sell in Canada.
 Both ELDEPRYL and PARKINYL contain the same active ingredient and are intended for treatment of Parkinson's disease but PARKINYL will have its own distinctive features.
 The active ingredient in both PARKINYL AND ELDEPRYL is deprenyl, an old drug discovered many years ago in Hungary and no longer under patent.
 Canguard understands that Deprenyl Research has Canadian rights to the brand name, ELDEPRYL, and to a patent on one production process for deprenyl. Canguard and Pharmascience are completely informed about this patent and will not infringe it in their production of deprenyl.
 PARKINYL is being developed for world markets and patent issues have been considered on a global basis. Licensing agreements for the sale and distribution of PARKINYL through corporate alliance overseas are already under negotiation.
 The Canguard management team has more than 35 years experience in the pharmaceutical industry. This experience includes the development, registration and marketing of new drugs in both entrepreneurial and corporate multinational settings.
 Dr. John B. Armstrong, Canguard's president and chief executive officer, stressed that Canguard is neither a generic nor a one- product company. He went on to say, ''The experience of Canguard's management team, the competitive features of PARKINYL, and the strength of our corporate partners will ensure that our product captures and maintains a generous market share. Canguard will continue to build its pharmaceutical business on the strength of innovative products now in its pipeline and soon to be launched into world markets.''
 -0- 11/25/91
 /CONTACT: Dr. John B. Armstrong, M.D., Ph.D., president and director of Canguard, 604-682-1777/
 (CGD.) CO: Canguard Health Technologies Inc. ST: British Columbia IN: HEA SU:


CH -- LA017 -- 6811 11/25/91 11:33 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 25, 1991
Words:369
Previous Article:ISIAH THOMAS RENEWS CONTRACT WITH TOYOTA
Next Article:SAGE ANALYTICS INTERNATIONAL REPORTS THREE NEW CONTRACTS
Topics:


Related Articles
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO LAWSUIT ANNOUNCED IN PRESS ON DEC. 3
CANGUARD HEALTH TECHNOLOGIES ANNOUNCES LAWSUIT UPDATE
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
CANGUARD HEALTH TECHNOLOGIES ADJOURNMENT AGREEMENT
CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE
CANGUARD ANNOUNCES PRIVATE PLACEMENT AND APPOINTMENT OF FISCAL AGENT
CANGUARD AND DEPRENYL RESEARCH LAWSUIT ADJOURNED TODAY; NO RESTRICTIONS IMPOSED ON CANGUARD
CANGUARD SERVES NOTICE OF MOTION, FINAL AFFIDAVITS ON DEPRENYL RESEARCH; ANNOUNCES NEW BUSINESS DEVELOPMENTS
CANGUARD HEALTH TECHNOLOGIES INC. RELEASES DETAILS OF ANNUAL REPORT TO SHAREHOLDERS
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters